Alterations in the host transcriptome in vitro following Rift Valley fever virus infection

In vitro neutralizing antibodies have been often correlated with protection against Rift Valley fever virus (RVFV) infection. We have reported previously that a single inoculation of sucrose-purified modified vaccinia Ankara (MVA) encoding RVFV glycoproteins (rMVAGnGc) was sufficient to induce a protective immune response in mice after a lethal RVFV challenge. Protection was related to the presence of glycoprotein specific CD8+ cells, with a low-level detection of in vitro neutralizing antibodies. In this work we extended those observations aimed to explore the role of humoral responses after MVA vaccination and to study the contribution of each glycoprotein antigen to the protective efficacy. Thus, we tested the efficacy and immune responses in BALB/c mice of recombinant MVA viruses expressing either glycoprotein Gn (rMVAGn) or Gc (rMVAGc). In the absence of serum neutralizing antibodies, our data strongly suggest that protection of vaccinated mice upon the RVFV challenge can be achieved by the activation of cellular responses mainly directed against Gc epitopes. The involvement of cellular immunity was stressed by the fact that protection of mice was strain dependent. Furthermore, our data suggest that the rMVA based single dose vaccination elicits suboptimal humoral immune responses against Gn antigen since disease in mice was exacerbated upon virus challenge in the presence of rMVAGnGc or rMVAGn immune serum. Thus, Gc-specific cellular immunity could be an important component in the protection after the challenge observed in BALB/c mice, contributing to the elimination of infected cells reducing morbidity and mortality and counteracting the deleterious effect of a subneutralizing antibody immune response.

Download Full-text

Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome

Antiviral Research ◽

10.1016/j.antiviral.2014.06.010 ◽

2014 ◽

Vol 109 ◽

pp. 64-67 ◽

Cited By ~ 7

Author(s):

Gema Lorenzo ◽

Miguel Rodríguez-Pulido ◽

Elena López-Gil ◽

Francisco Sobrino ◽

Belén Borrego ◽

...

Keyword(s):

Virus Infection ◽

Rift Valley ◽

Rift Valley Fever ◽

Rift Valley Fever Virus ◽

Fever Virus ◽

Valley Fever ◽

Rna Transcripts

Download Full-text

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy

Journal of Virology ◽

10.1128/jvi.01105-15 ◽

2015 ◽

Vol 89 (17) ◽

pp. 9124-9127 ◽

Cited By ~ 1

Author(s):

N. Oreshkova ◽

L. Spel ◽

R. P. M. Vloet ◽

P. J. Wichgers Schreur ◽

R. J. M. Moormann ◽

...

Keyword(s):

Cancer Immunotherapy ◽

Rift Valley ◽

Rift Valley Fever ◽

Rift Valley Fever Virus ◽

Fever Virus ◽

Preliminary Evaluation ◽

Valley Fever ◽

Human Dendritic Cells

Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+T cellsin vitroand that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cellsin vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.

Download Full-text

Wolbachia effects on Rift Valley fever virus infection in Culex tarsalis mosquitoes

PLoS Neglected Tropical Diseases ◽

10.1371/journal.pntd.0006050 ◽

2017 ◽

Vol 11 (10) ◽

pp. e0006050 ◽

Cited By ~ 7

Author(s):

Brittany L. Dodson ◽

Elizabeth S. Andrews ◽

Michael J. Turell ◽

Jason L. Rasgon

Keyword(s):

Virus Infection ◽

Rift Valley ◽

Rift Valley Fever ◽

Rift Valley Fever Virus ◽

Fever Virus ◽

Culex Tarsalis ◽

Valley Fever

Download Full-text

An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus

Epidemiology and Infection ◽

10.1017/s0950268808001696 ◽

2009 ◽

Vol 137 (9) ◽

pp. 1309-1318 ◽

Cited By ~ 37

Author(s):

M. T. HEISE ◽

A. WHITMORE ◽

J. THOMPSON ◽

M. PARSONS ◽

A. A. GROBBELAAR ◽

...

Keyword(s):

Rift Valley ◽

Rift Valley Fever ◽

Rift Valley Fever Virus ◽

Fluorescent Antibody ◽

Severe Disease ◽

Neutralizing Antibody ◽

Fever Virus ◽

Antibody Responses ◽

Valley Fever

SUMMARYRift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus (genusPhlebovirus) associated with severe disease in livestock and fatal encephalitis or haemorrhagic fever in a proportion of infected humans. Although live attenuated and inactivated vaccines have been used in livestock, and on a limited scale in humans, there is a need for improved anti-RVFV vaccines. Towards this goal, Sindbis virus replicon vectors expressing the RVFV Gn and Gc glycoproteins, as well as the non-structural nsM protein, were constructed and evaluated for their ability to induce protective immune responses against RVFV. These replicon vectors were shown to produce the RVFV glycoproteins to high levelsin vitroand to induce systemic anti-RVFV antibody responses in immunized mice, as determined by RVFV-specific ELISA, fluorescent antibody tests, and demonstration of a neutralizing antibody response. Replicon vaccination also provided 100% protection against lethal RVFV challenge by either the intraperitoneal or intranasal route. Furthermore, preliminary results indicate that the replicon vectors elicit RVFV-specific neutralizing antibody responses in vaccinated sheep. These results suggest that alphavirus-based replicon vectors can induce protective immunity against RVFV, and that this approach merits further investigation into its potential utility as a RVFV vaccine.

Download Full-text